AZN.L
現在値
8,845.00GBp変化
177.00(+2.04%)出来高
4,348,813本日のレンジ
-
8,982.0052週レンジ
-
8,982.00∙ 約20分前の相場を表示しています。
Sept 24 (Reuters) - Merck & Co Inc <MRK.N>::LYNPARZA® (OLAPARIB) IN COMBINATION WITH ABIRATERONE SIGNIFICANTLY DELAYED DISEASE PROGRESSION IN PATIENTS REGARDLESS OF BIOMARKER STATUS IN PROPEL PHASE 3 TRIAL IN FIRST-LINE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).MERCK - INDEPENDENT DATA MONITORING COMMITTEE CONCLUDED TRIAL MET PRIMARY ENDPOINT OF RPFS IN MEN WITH MCRPC WHO HAD NOT RECEIVED TREATMENT IN FIRST-LINE SETTING.MERCK & CO INC - SAFETY AND TOLERABILITY WERE CONSISTENT WITH KNOWN PROFILES OF EACH MEDICINE IN PHASE 3 PROPEL TRIAL.MERCK & CO INC - PHASE 3 PROPEL TRIAL OS DATA ARE STILL IMMATURE, AND TRIAL WILL CONTINUE TO ASSESS OS AS A KEY SECONDARY ENDPOINT.
Sept 24 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT.ASTRAZENECA - FIRST PARP INHIBITOR TO DEMONSTRATE CLINICAL BENEFIT IN COMBINATION WITH A NEW HORMONAL AGENT IN THIS SETTING.ASTRAZENECA - LYNPARZA IN COMBINATION WITH ABIRATERONE SIGNIFICANTLY DELAYED DISEASE PROGRESSION IN ALL-COMERS IN PROPEL PHASE III TRIAL IN 1ST-LINE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.ASTRAZENECA - TRIAL ALSO SHOWED A TREND AT THIS INTERIM ANALYSIS TOWARDS IMPROVED OVERALL SURVIVAL.ASTRAZENECA - TRIAL ALSO SHOWED A TREND AT THIS INTERIM ANALYSIS TOWARDS IMPROVED OVERALL SURVIVAL (OS).ASTRAZENECA - DATA ARE STILL IMMATURE AND TRIAL WILL CONTINUE TO ASSESS OS AS A KEY SECONDARY ENDPOINT.ASTRAZENECA - SAFETY AND TOLERABILITY WERE CONSISTENT WITH KNOWN PROFILES OF EACH MEDICINE.
Sept 21 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT.ASTRAZENECA - ASTRAZENECA TO INVEST $360M IN ADVANCED MANUFACTURING FACILITY IN IRELAND.ASTRAZENECA - ASTRAZENECA TO INVEST $360M IN ADVANCED MANUFACTURING FACILITY IN IRELAND.ASTRAZENECA - INVESTMENT WILL TRANSFORM DEVELOPMENT AND COMMERCIALISATION OF NEW MEDICINES.ASTRAZENECA - $360M PLANNED INVESTMENT AT ALEXION CAMPUS IN COLLEGE PARK, DUBLIN, IS EXPECTED TO CREATE ABOUT 100 HIGHLY SKILLED DIRECT JOBS.ASTRAZENECA - $360M PLANNED INVESTMENT AT ALEXION CAMPUS IN COLLEGE PARK, DUBLIN, IS EXPECTED TO CREATE ABOUT 100 HIGHLY SKILLED DIRECT JOBS.ASTRAZENECA - INVESTMENT PROGRAMME IS EXPECTED TO SIGNIFICANTLY REDUCE COMMERCIALISATION LEAD TIMES, COSTS.
Sept 9 (Reuters) - Medicines and Healthcare products Regulatory Agency::MHRA STATEMENT ON BOOSTER DOSES OF PFIZER AND ASTRAZENECA COVID-19 VACCINES.MHRA SAYS IT WILL BE FOR JVCI TO ADVISE ON WHETHER BOOSTER JABS WILL BE GIVEN AND IF SO, WHICH VACCINES SHOULD BE USED.MHRA SAYS PLEASED TO CONFIRM THAT THE COVID-19 VACCINES MADE BY PFIZER AND ASTRAZENECA CAN BE USED AS SAFE AND EFFECTIVE BOOSTER DOSES. ((Reuters.Briefs@thomsonreuters.com;)).
Sept 9 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - PT027 PHIII ASTHMA TRIALS MET PRIMARY ENDPOINTS.ASTRAZENECA - FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFICANT BENEFITS FOR ASTHMA PATIENTS IN MANDALA AND DENALI PHASE III TRIALS.ASTRAZENECA - PT027 SIGNIFICANTLY REDUCED RISK OF SEVERE EXACERBATIONS COMPARED TO ALBUTEROL IN PATIENTS WITH MODERATE TO SEVERE ASTHMA.ASTRAZENECA - PT027 SIGNIFICANTLY IMPROVED LUNG FUNCTION COMPARED TO INDIVIDUAL COMPONENTS IN MILD TO MODERATE ASTHMA IN DENALI TRIAL.
Sept 8 (Reuters) - European Medicines Agency::EMA: EMA PUBLISHED NEW SAFETY UPDATES FOR COMIRNATY, COVID-19 VACCINE JANSSEN, SPIKEVAX AND VAXZEVRIA: 08/09/2021.EMA: PAIN IN LEGS & ARMS OR STOMACH AND INFLUENZA-LIKE SYMPTOMS HAVE ALSO BEEN INCLUDED IN PRODUCT INFORMATION AS SIDE EFFECTS OF ASTRAZENECA VACCINE.EMA: ASTRAZENECA COVID-19 VACCINE PRODUCT INFORMATION WILL BE UPDATED WITH GUILLAIN-BARRÉ SYNDROME (GBS) AS A SIDE EFFECT.EMA, ON MODERNA COVID-19 SHOT: REQUESTED CO TO FURTHER SPECIFY CHARACTERISTICS OF DELAYED INJECTION SITE REACTION, SUCH AS TYPICAL TIME TO ONSET, SEVERITY OF REACTIONS.Further company coverage: AZN.L. ((Reuters.Briefs@thomsonreuters.com;)).
Sept 3 (Reuters) - European Commission::EC: EU AND ASTRAZENECA HAVE REACHED AN AGREEMENT WHICH WILL SECURE THE DELIVERY OF THE REMAINING COVID-19 VACCINE DOSES TO MEMBER STATES.EC - AGREEMENT WILL ALSO END THE PENDING LITIGATION BEFORE THE BRUSSELS COURT..EC - AGREEMENT WITH AZ WILL BRING THE TOTAL NUMBER OF DOSES DELIVERED TO 300 MILLION DOSES AS AGREED UNDER THE CONTRACT..EC - MEMBER STATES WILL BE PROVIDED WITH REGULAR DELIVERY SCHEDULES AND CAPPED REBATES WILL APPLY IN THE EVENT OF ANY DELAYED DOSES..EC: SETTLEMENT PROVIDES FOR FIRM COMMITMENT BY ASTRAZENECA TO DELIVER, IN ADDITION TO AROUND 100 MILLION DOSES DELIVERED UNTIL END OF Q2, 135 MILLION DOSES BY END OF 2021.EC: SETTLEMENT AGREEMENT ALSO PROVIDES FOR FIRM COMMITMENT BY ASTRAZENECA TO DELIVER TO REMAINING DOSES (65 MILLION) BY END OF MARCH 2022.Further company coverage: AZN.L. ((Reuters.Briefs@thomsonreuters.com ;;)).
Aug 31 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL.GSK - ADVANCE TO PHASE 3 FOLLOWS POSITIVE INTERIM PHASE 1/2 IMMUNOGENICITY AND SAFETY DATA.GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL.GSK - GLOBAL CLINICAL TRIAL WILL EVALUATE VACCINE CANDIDATE GBP510 AGAINST AZ/OXFORD COVID-19 VACCINE.GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022, SUBJECT TO DATA AND REGULATORY REVIEW.GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022.GSK - NO SAFETY CONCERNS HAVE BEEN IDENTIFIED TO DATE IN THIS ONGOING STUDY..GSK - ALSO ASSESSING WHETHER AN INVESTIGATIONAL MONOCLONAL ANTIBODY, OTILIMAB, CAN HELP SEVERELY ILL COVID-19 PATIENTS AGED OVER 70.GSK - GSK IS ALSO EXPLORING POTENTIAL THERAPEUTIC OR TREATMENT OPTIONS FOR COVID-19 PATIENTS.
Aug 26 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT.ASTRAZENECA - ALXN1840 DEMONSTRATED APPROXIMATELY THREE TIMES GREATER COPPER MOBILISATION FROM TISSUES THAN STANDARD-OF-CARE TREATMENTS.ASTRAZENECA - ALXN1840 FOCUS PHASE III TRIAL IN WILSON DISEASE MET PRIMARY ENDPOINT DEMONSTRATING IMPROVEMENT IN COPPER MOBILISATION FROM TISSUES.ASTRAZENECA - ALXN1840 MET PRIMARY ENDPOINT WITH A STATISTICALLY SIGNIFICANT IMPROVEMENT IN DAILY MEAN COPPER MOBILISATION FROM TISSUES.ASTRAZENECA - ALXN1840 WAS GENERALLY WELL-TOLERATED.ASTRAZENECA - ALEXION IS WORKING CLOSELY WITH HEALTH AUTHORITIES WORLDWIDE AND INTENDS TO SUBMIT THESE DATA FOR REVIEW IN COMING MONTHS..ASTRAZENECA - ALEXION IS WORKING CLOSELY WITH HEALTH AUTHORITIES WORLDWIDE AND INTENDS TO SUBMIT THESE DATA FOR REVIEW IN COMING MONTHS.
Aug 20 (Reuters) - AstraZeneca PLC <AZN.L>::ASTRAZENECA PLC - UPDATE ON ULTOMIRIS PHASE III ALS TRIAL.ASTRAZENECA - ALEXION IS DISCONTINUING CHAMPION-ALS, GLOBAL PHASE III CLINICAL TRIAL OF ULTOMIRIS.ASTRAZENECA - ALEXION IS DISCONTINUING CHAMPION-ALS, GLOBAL PHASE III CLINICAL TRIAL OF ULTOMIRIS (RAVULIZUMAB) IN ADULTS WITH AMYOTROPHIC LATERAL SCLEROSIS.ASTRAZENECA - THIS DECISION IS BASED ON RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE (IDMC).ASTRAZENECA - NO NEW SAFETY FINDINGS WERE OBSERVED AND DATA WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF ULTOMIRIS.ASTRAZENECA - IDMC RECOMMENDED THAT TRIAL BE DISCONTINUED DUE TO LACK OF EFFICACY.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。